Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-β pathways in human breast cancer cells

Molecular Endocrinology

Volumn 18, Issue 7, 2004, Pages 1643-1657

  Buck, Miriam B ^a,b   Pfizenmaier, Klaus ^c   Knabbe, Cornelius ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN A; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; HUMANS; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TAMOXIFEN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 3042829477     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0278     Document Type: Article

References (55)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
2. Wolf DM, Jordan VC 1993 William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat 27:27-40
3. Morris C, Wakeling A 2002 Fulvestrant ('Faslodex') - a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 9:267-276
4. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
5. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12:1605-1618
6. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
7. Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
8. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB 1987 Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428
9. Knabbe C, Kopp A, Hilgers W, Lang D, Muller V, Zugmaier G, Jonat W 1996 Regulation and role of TGF β production in breast cancer. Ann NY Acad Sci 784:263-276
10. Muller V, Jensen EV, Knabbe C 1998 Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 58:263-267
11. Buck M, von der Fecht J, Knabbe C 2002 Antiestrogenic regulation of transforming growth factor β receptors I and II in human breast cancer cells. Ann NY Acad Sci 963:140-143
12. Moses HL 1992 TGF-β regulation of epithelial cell proliferation. Mol Reprod Dev 32:179-184
13. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB 1989 Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141:353-361
14. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J 1994 Mechanism of activation of the TGF-β receptor. Nature 370:341-347
15. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, Nishida E 1999 Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J Biol Chem 274:27161-27167
16. Petritsch C, Beug H, Balmain A, Oft M 2000 TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev 14:3093-3101
17. Heldin CH, Miyazono K, ten Dijke P 1997 TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471
18. Frey RS, Mulder KM 1997 Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res 57:628-633
19. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL 2000 Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803-36810
20. Kyriakis JM, Avruch J 2001 Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869
21. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y, Nishizawa M, Fujisawa J, Inoue K 2003 p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38:879-889
22. Obrero M, Yu DV, Shapiro DJ 2002 Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 277:45695-45703
23. Mandlekar S, Yu R, Tan TH, Kong AN 2000 Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60:5995-6000
24. Mandlekar S, Kong AN 2001 Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-477
25. Reddel RR, Murphy LC, Sutherland RL 1983 Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res 43:4618-4624
26. English JM, Cobb MH 2002 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45
27. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J 1992 TGFβ signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014
28. Yakymovych I, Engstrom U, Grimsby S, Heldin CH, Souchelnytskyi S 2002 Inhibition of transforming growth factor-β signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF β type I receptor kinase. Biochemistry 41:11000-11007
29. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kem SE 1998 Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1:611-617
30. Dennler S, Huet S, Gauthier JM 1999 A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 18:1643-1548
31. de Caestecker MP, Hemmati P, Larisch-Bloch S, Ajmera R, Roberts AB, Lechleider RJ 1997 Characterization of functional domains within Smad4/DPC4. J Biol Chem 272:13690-13696
32. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044
33. Zhang CC, Shapiro DJ 2000 Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 275:479-486
34. Kim JY, Choi JA, Kim TH, Yoo YD, Kim JI, Lee YJ, Yoo SY, Cho CK, Lee YS, Lee SJ 2002 Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 190:29-37
35. Maas RA, Bruning PF, Top B, Breedijk AJ, Peterse HL 1995 Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment response. Cancer Lett 97:107-116
36. Watanabe H, de Caestecker MP, Yamada Y 2001 Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-β-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 276:14466-14473
37. Selvamurugan N, Fung Z, Partridge NC 2002 Transcriptional activation of collagenase-3 by transforming growth factor-β1 is via MAPK and Smad pathways in human breast cancer cells. FEBS Lett 532:31-35
38. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA 2002 Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571-24578
39. O'Reilly MA, Geiser AG, Kim SJ, Bruggeman LA, Luu AX, Roberts AB, Sporn MB 1992 Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-β2 promoter. J Biol Chem 267:19938-19943
40. Jiang Y, Chen C, Li Z, Quo W, Gegner JA, Lin S, Han J 1996 Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J Biol Chem 271:17920-17926
41. Li H, Wicks WD 2001 Retinoblastoma protein interacts with ATF2 and JNK/p38 in stimulating the transforming growth factor-β2 promoter. Arch Biochem Biophys 394:1-12
42. Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, Kim SJ 2002 Transcriptional regulation of the transforming growth factor β type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem 277:5168-5174
43. Jennings R, Alsarraj M, Wright KL, Munoz-Antonia T 2001 Regulation of the human transforming growth factor β type II receptor gene promoter by novel Sp1 sites. Oncogene 20:6899-6909
44. Fralix KD, Zhao S, Venkatasubbarao K, Freeman JW 2003 Rap1 reverses transcriptional repression of TGF-β type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1. J Cell Physiol 194:88-99
45. Choi SG, Yi Y, Kim YS, Kato M, Chang J, Chung HW, Hahm KB, Yang HK, Rhee HH, Bang YJ, Kim SJ 1998 A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor. J Biol Chem 273:110-117
46. Ammanamanchi S, Brattain MG 2001 Sp3 is a transcriptional repressor of transforming growth factor-β receptors. J Biol Chem 276:3348-3352
47. Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A 2001 The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276:13664-13674
48. Balasubramanian S, Efimova T, Eckert RL 2002 Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J Biol Chem 277:1828-1836
49. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM 1998 Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100
50. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT, Wang XF 1997 Tumor suppressor Smad4 is a transforming growth factor β-inducible DNA binding protein. Mol Cell Biol 17:7019-7028
51. Feng XH, Lin X, Derynck R 2000 Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-β. EMBO J 19:5178-5193
52. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ 1997 DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14:1891-1899
53. Itoh S, Itoh F, Goumans MJ, Ten Dijke P 2000 Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem 267:6954-6967
54. Massague J, Wotton D 2000 Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19:1745-1754
55. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2496-2500